{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133757","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.171490+00:00","generated_at":"2026-06-02T14:54:06.670826+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Veru reports Q2 fiscal 2024 net loss $10M, cash $34.7M; enobosarm Phase 2b enrolling","bullets":["Fiscal Q2 net revenues $4.1M (down 38% YoY); net loss $10.0M ($0.07/share) vs $33.8M loss ($0.42) prior year.","Cash and equivalents $34.7M at March 31, 2024, up from $9.6M at Sept 30, 2023.","Phase 2b enobosarm+semaglutide weight loss trial actively enrolling; topline results expected end of 2024.","Extension trial to test muscle maintenance after GLP-1 discontinuation; results expected Q2 2025.","Assembled five-MD Scientific Advisory Board for high quality weight loss program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133757","json":"https://secwatch.observer/filing/0001193125-24-133757.json","markdown":"https://secwatch.observer/filing/0001193125-24-133757.md","text":"https://secwatch.observer/filing/0001193125-24-133757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/0001193125-24-133757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/d820381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T14:54:06.670826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"136e65ddc6b6a641ac965cdf986569787a2d62d1","claim":"VERU INC. reported the quarter and six months ended March 31, 2024 results: revenue $4.1 million, net income $10.0 million, or $0.07 per share, EPS $0.07 per share.","evidence_excerpt":"the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025. Second Quarter Financial Summary: Fiscal 2024 vs Fiscal 2023 • Net revenues decreased to $4.1 million from $6.6 million • Gross profit decreased to $0.7 million from $4.1 million • Research and development expenses decreased to $3.0 million from $17.9 million, as restated •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312524133757/0001193125-24-133757-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and six months ended March 31, 2024"},{"label":"Revenue","value":"$4.1 million"},{"label":"Net income","value":"$10.0 million, or $0.07 per share"},{"label":"EPS","value":"$0.07 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}